V
Vial
A tech-enabled CRO delivering superior clinical trial outcomes
About Vial
Vial.com is a technology-driven Contract Research Organization (CRO) that operates in the global clinical trials market. Its mission is to empower scientists to cure all human diseases by delivering faster and more efficient trials. The company serves clients in the pharmaceutical and biotechnology sectors, helping them conduct clinical trials more efficiently and at a larger scale.
Vial.com's business model revolves around its proprietary Vial Technology Platform. This platform uses connected systems and intuitive design to streamline the clinical trial process, moving it away from traditional paper-based methods. The platform allows for seamless transitions between different visits and phases of a trial, redefining how these trials are conducted.
The company also offers a fixed-fee pricing model, which helps clients maximize their return on investment (ROI). This means that clients pay a set price for the service, regardless of the time and resources it takes to complete the trial. This model provides cost certainty for clients and incentivizes Vial.com to conduct trials as efficiently as possible.
Vial.com also provides thought leadership in the industry, publishing white papers on topics such as the future landscape of dermatology clinical trials and best practices for patient recruitment in oncology.
In summary, Vial.com is a technology-driven CRO that uses its proprietary platform to conduct clinical trials more efficiently and at a larger scale. It serves clients in the pharmaceutical and biotech sectors and operates on a fixed-fee pricing model.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- San Francisco, United States
- Employees
- 161
- Open positions
- 7
- Dealroom signal
- 63.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech
- Business model
- Marketplace & ecommerce
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2022 | $67M | $268M | Adam Rothenberg · David Tisch · Hemant Taneja · Zak Kukoff | ↗ |
| SEEDOther financing | Apr 2021 | $0 | — | Buckley Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Vial is 11K monthly website visits, up 0% over the last three months. Vial's team declined 8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Buckley Ventures
Series A21 investors entered at this stage
Adam Rothenberg
David Tisch
Hemant Taneja
Zak Kukoff
Josh Buckley
Greg R. Meland
TJ Nahigian
Byers Capital
General Catalyst
BoxGroup
Blake Byers- DADan Ashton
JD Ross- JSJeff Silverstein
Elena Viboch
Gordon Wintrob
Connor Zwick
Nikhil Krishnan
David Hsu
Nimi Katragadda
Spike Lipkin
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vial on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vial’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







